Nasal Spray

(COVID-19, Flu & Common Cold)

December 2022 Confidential Information

 Mechanism

Covixyl Nasal Spray creates protective barriers by coating the entire nasal passage.
This barrier blocks the coronavirus spike from binding to the ACE2 receptors on
the cell and the virus can’t gain a foothold in the nasal passage.

Coronavirus
Nasopharynx cells Spikes
(entry point of virus)

AC2 Receptor
 Respiratory viruses

Covixyl Nasal Spray effectively inhibits most of respiratory viruses over 99% by
unique blocking mode of action.

Log Virus
Disease Virus Type
Reduction (10) Reduction (%)

COVID-19 Delta 3.20 over 99.9%

COVID-19 Omicron 2.10 over 99%

Flu Influenza A (H1N1) 5.04 over 99.999%

Common cold Human coronavirus 3.37 over 99.9%

Common cold,
Human RS virus 2.75 over 99%
Pneumonia

Diarrhea, Fever Rotavirus A 2.13 over 99%

 Coronavirus variants

Covixyl Nasal Spray effectively neutralizes Delta and Omicron variants over 99%
based on live viruses test at BSL-3 laboratory.

Covixyl vs. Delta Covixyl vs. Omicron

8
10 10
10

9
10
7
10
8
10

TCID50/ml
TCID50/ml

6
10
7 10

6
10 5
10
5
10
4
10
4
10 200µg/ml 250µg/ml
0
0 100µg/ml 200µg/ml
TCID50 Assay in Vero-TMPRSS2 cells with Delta variant TCID50 Assay in TMPRSS2 cells with Omicron variant
Control group Control group

treated with Covixyl (dilution of 100~200µg/ml) treated with Covixyl (dilution of 200~250µg/ml)
 Safety

Covixyl Nasal Spray has passed all standard safety testing protocol without harmful
effect to nasal passage and all ingredients formulated are listed in GRAS of FDA.
Safety Tests

Tests Test Method Outcomes Food Preservatives

Cytotoxicity ISO 10993-05 No cytotoxic with grade zero

Skin Irritation ISO 10993-10 No irritation with grade zero

Skin Sensation ISO 10993-10 No sensation with grade zero

Skin Sensitization ISO 10993-10 No sensitization with grade zero

Eye Irritation (BCOP) OECD guideline No irritation within IVIS

Endotoxin NCI guideline Below the limit of detection <0.5 (53)

β-Glucans NCI guideline Undetectable <5 (87)

* Active: ELAH 0.1% (Ethyl Lauroyl Arginate Hydrochloride)

 Clinical Trial

Human clinical trial proves the safety and efficacy of Covixyl Nasal Spray against
COVID-19.

Pre-clinical Clinical Trial

➢ No adverse events or
side effects found

➢ CRO: Global Clinical Trial (USA) √

➢ No adverse interaction
➢ No body weight change
➢ 99.9% virus neutralization
. Period: May ~ October 2021
. Phase of study: Pivotal
. Location: Miami, FL
. No. of Infected Patients: 30
. Use: 2 times/day x 6 days
➢ 400% more infection-free
subject were observed in
Covixyl group vs. placebo
 Global Recognition

Cascade Assay Award to Covixyl Nasal Spray and funded joint research with NCI /
Research paper published in WHO global open access & peer-review in SCI journal
/ 5th Int’l Virology & Infectious Diseases as keynote speaker

➢ Prophylactic and Therapeutic Effects of ELAH on

SARS-CoV-2 Infections (April 2022; global open
access)
 Regulatory

The device is approved in UK while CE & FDA are on-going process along with
global patents and 3 qualified manufacturing sites.

➢ Regulatory

➢ Patent & Trademark ➢ Manufacturing (USA, UK, Korea)

 Sales

Covixyl Nasal Spray is available at Walmart and Amazon in the US and it has been
marketed as licensed brand of BioSure in UK.

www.walmart.com www.amazon.com www.sprayprotectgo.com

 Application

Covixyl Nasal Spray is preventative measures against COVID-19, Flu & Common Cold.
It is designed to work alongside vaccines and masks.

➢ Anywhere & Anytime : before going out,

work or school, when commuting, in the
crowded areas, or public places.

➢ 2 times per day

Reapply at anytime to maintain protection.

➢ Clinically proven to safely and effectively

provide protection against COVID-19, Flu,
and common colds
 Summary

Covixyl Nasal Spray protects from COVID-19, Flu and Common Colds anywhere
and anytime.

Summary of Product

➢ Brand: COVIXYL Nasal Spray

➢ Size: 400 sprays (=20ml)

➢ Use period: 50 days (2 times/day)

➢ MSRP: U$18.99 / Bottle ($0.38/day)

➢ Claims
Protect against respiratory
viruses causing COVID-19 & Flu

➢ Regulatory: Approved by medical

device in UK, Korea, and South
America (pending FDA & CE)